Tercica exercises option for IGF-1 plus IGFBP-3

TRCA exercised an option and paid Genentech (DNA) $1.3 million for an exclusive license to the combination of insulin-like growth factor-1 ( IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). DNA retains worldwide rights to the combination therapy for CNS indications and retains ex-U.S. rights for diabetes. ...